Literature DB >> 10788705

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

E Vanmechelen1, H Vanderstichele, P Davidsson, E Van Kerschaver, B Van Der Perre, M Sjögren, N Andreasen, K Blennow.   

Abstract

Hyperphosphorylation of the microtubule-associated protein tau is specifically found in those brain cells affected in several tauopathies. Tau has also been consistently found to be present in the cerebrospinal fluid (CSF). Here we report the quantification in CSF of tau phosphorylated at Thr 181 using an immunoassay with a synthetic peptide for standardization. The choice of the peptide was based on fine mapping of a phospho-dependent antibody, AT270 (P(176)PAPKT(p)P(132))and a human specific tau antibody, HT7 (P(159)PGQK(163)). CSF-phospho-tau levels were increased in Alzheimer patients (23.5+/-10.1 pM, P<0.01) compared with age-matched controls (15.9+/-5.7 pM), while decreased in patients with frontotemporal dementia (8.6+/-3.9 pM; P<0.01). In every diagnostic group, a highly significant correlation was found between total tau and phospho-tau (Alzheimer's disease, r(2)=0.73; frontotemporal dementia, r(2)=0.43; Control, r(2)=0.42), suggesting that the degree of phosphorylation of CSF-tau changes in different clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10788705     DOI: 10.1016/s0304-3940(00)01036-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  133 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.

Authors:  Sara Landgren; Malin von Otter; Mona Seibt Palmér; Caroline Zetterström; Staffan Nilsson; Ingmar Skoog; Deborah R Gustafson; Lennart Minthon; Anders Wallin; Niels Andreasen; Nenad Bogdanovic; Jan Marcusson; Kaj Blennow; Henrik Zetterberg; Petronella Kettunen
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

3.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

Review 4.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

5.  Age and diagnostic performance of Alzheimer disease CSF biomarkers.

Authors:  N Mattsson; E Rosén; O Hansson; N Andreasen; L Parnetti; M Jonsson; S-K Herukka; W M van der Flier; M A Blankenstein; M Ewers; K Rich; E Kaiser; M M Verbeek; M Olde Rikkert; M Tsolaki; E Mulugeta; D Aarsland; P J Visser; J Schröder; J Marcusson; M de Leon; H Hampel; P Scheltens; A Wallin; M Eriksdotter-Jönhagen; L Minthon; B Winblad; K Blennow; H Zetterberg
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

6.  The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.

Authors:  Whitney Wharton; James H Stein; Claudia Korcarz; Jane Sachs; Sandra R Olson; Henrik Zetterberg; Maritza Dowling; Shuyun Ye; Carey E Gleason; Gail Underbakke; Laura E Jacobson; Sterling C Johnson; Mark A Sager; Sanjay Asthana; Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

7.  No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Authors:  Jan J Krut; Richard W Price; Henrik Zetterberg; Dietmar Fuchs; Lars Hagberg; Aylin Yilmaz; Paola Cinque; Staffan Nilsson; Magnus Gisslén
Journal:  Virulence       Date:  2016-07-19       Impact factor: 5.882

8.  Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

9.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.

Authors:  Ming-Jang Chiu; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Ta-Fu Chen; Jen-Je Chieh; Hsin-Hsien Chen; Ting-Chi Chen; Chia-Shin Ho; Shuo-Fen Chang; Hao Chun Liu; Chin-Yih Hong; Hong-Chang Yang
Journal:  ACS Chem Neurosci       Date:  2013-10-23       Impact factor: 4.418

10.  Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Authors:  Volker Welge; Oliver Fiege; Piotr Lewczuk; Brit Mollenhauer; Hermann Esselmann; Hans-Wolfgang Klafki; Stefanie Wolf; Claudia Trenkwalder; Markus Otto; Johannes Kornhuber; Jens Wiltfang; Mirko Bibl
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.